Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

Neurology

Volumn 72, Issue 8, 2009, Pages 772-773

  Chamberlain, Marc C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; IRINOTECAN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

CANCER SURVIVAL; CONTRAST ENHANCEMENT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; LETTER; LUNG EMBOLISM; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR VOLUME; BRAIN TUMOR; GLIOMA; NOTE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 62349110751     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000339387.03225.0a     Document Type: Letter

References (5)

1. AD Norden GS Young K Setayesh Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence Neurology 70 2008 779 787
2. JJ Vredenburgh A Desjardins JE Herndon Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 2007 1253 1259
3. WB Pope A Lai P Nghiemphu P Mischel TF Cloughesy MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology 66 2006 1258 1260
4. MD Prados K Lamborn WKA Yung A phase 2 trail of irinotecan (CPT-11) in patients with recurrent malignant glioma: a NABTC study Neuro-Oncology 8 2006 189 193
5. TT Batchelor AG Sorensen E diTomaso AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95